# BRAF in non-small cell lung cancer

4 EU-approved indications in non-small cell lung cancer need a BRAF result: encorafenib (advanced), trametinib (advanced), dabrafenib (advanced) and binimetinib (advanced).

## Approved indications

### BRAF mutation

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Binimetinib](https://oncolabels.com/drugs/binimetinib) (Mektovi) | BRAF V600E | + encorafenib | Advanced | - |
| [Dabrafenib](https://oncolabels.com/drugs/dabrafenib) (Tafinlar) | BRAF V600 | + trametinib | Advanced | - |
| [Encorafenib](https://oncolabels.com/drugs/encorafenib) (Braftovi) | BRAF V600E | + binimetinib | Advanced | - |
| [Trametinib](https://oncolabels.com/drugs/trametinib) (Mekinist) | BRAF V600 | + dabrafenib | Advanced | - |

## Label wording

- **Encorafenib** (Braftovi), Non-small cell lung cancer, advanced: “Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf)
- **Trametinib** (Mekinist), Non-small cell lung cancer, advanced: “Trametinib in combination with dabrafenib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf)
- **Dabrafenib** (Tafinlar), Non-small cell lung cancer, advanced: “Dabrafenib in combination with trametinib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf)
- **Binimetinib** (Mektovi), Non-small cell lung cancer, advanced: “Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/non-small-cell-lung-cancer/braf